Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare Biotechnology

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger)

Bullboard Posts

Comment by funky99on Aug 25, 2016 8:37am

96 Views

Post# 25175106

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:Execution

Knight Therapeutics secured territory rights for the below region in exchange of royalties and sales milestones payments. CAN: Canada, ISR: Israel, ROM: Romania, RUS: Russia, ZAF: Sub-Saharan Africa. US/Europe which are sizable markets are still proprietary to Antibe Therapeutics. Maybe they will strike another deal with another pharma as their plan seems for an exit strategy after phase II completion with a phase III plan prepared per MD&A and annual documents.

Bullboard Posts

Canadian government to fund Electric Royalties portfolio property